Arcadia Biosciences Financials
RKDA Stock | USD 3.15 0.15 4.55% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 5.02 | 3.75 |
|
|
The essential information of the day-to-day investment outlook for Arcadia Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Arcadia Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Arcadia Biosciences.
Net Income |
|
Arcadia | Select Account or Indicator |
Please note, the presentation of Arcadia Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcadia Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Arcadia Biosciences' management manipulating its earnings.
Arcadia Biosciences Stock Summary
Arcadia Biosciences competes with Better Choice, Bit Origin, Farmmi, Laird Superfood, and Planet Green. Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company was incorporated in 2002 and is headquartered in Davis, California. Arcadia Bio operates under Agricultural Inputs classification in the United States and is traded on NASDAQ Exchange. It employs 58 people.Specialization | Consumer Defensive, Food, Beverage & Tobacco |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0390142042 |
CUSIP | 039014204 039014105 039014303 |
Location | United States; U.S.A |
Business Address | 5950 Sherry Lane, |
Sector | Food Products |
Industry | Consumer Staples |
Benchmark | Dow Jones Industrial |
Website | www.arcadiabio.com |
Phone | 214 974 8921 |
Currency | USD - US Dollar |
Arcadia Biosciences Key Financial Ratios
Return On Equity | -0.67 | ||||
Profit Margin | (1.06) % | ||||
Operating Margin | (1.15) % | ||||
Price To Sales | 0.82 X | ||||
Revenue | 5.33 M |
Arcadia Biosciences Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 47.3M | 43.9M | 28.9M | 19.7M | 22.7M | 35.9M | |
Other Current Liab | 3.0M | 1.5M | 1.3M | 1.9M | 1.7M | 1.8M | |
Net Debt | (4.7M) | (25.4M) | (18.6M) | (5.5M) | (5.0M) | (5.2M) | |
Retained Earnings | (211.8M) | (226.5M) | (257.9M) | (271.8M) | (244.7M) | (256.9M) | |
Accounts Payable | 726K | 1.4M | 905K | 801K | 921.2K | 970.9K | |
Cash | 14.0M | 28.7M | 20.6M | 6.5M | 7.5M | 13.8M | |
Net Receivables | 1.4M | 1.4M | 1.2M | 514K | 462.6K | 767.9K | |
Inventory | 3.8M | 4.4M | 2.6M | 2.0M | 2.3M | 1.6M | |
Other Current Assets | 1.6M | 1.8M | 1.2M | 858K | 986.7K | 914.0K | |
Total Liab | 18.8M | 12.7M | 8.0M | 7.0M | 6.3M | 6.0M | |
Total Current Assets | 31.7M | 35.4M | 25.4M | 15.0M | 17.2M | 28.3M | |
Other Liab | 8.2M | 16.9M | 5.0M | 5.5M | 6.3M | 8.1M | |
Other Assets | 372K | 5.5M | 2.7M | 1.0 | 0.9 | 0.86 | |
Short Term Debt | 2.6M | 2.1M | 2.0M | 852K | 766.8K | 728.5K | |
Net Tangible Assets | 12.8M | 7.7M | 26.9M | 30.6M | 35.2M | 37.0M |
Arcadia Biosciences Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 5K | 47K | 20K | 289K | 260.1K | 247.1K | |
Total Revenue | 8.0M | 6.8M | 10.0M | 5.3M | 6.1M | 6.0M | |
Gross Profit | 2.8M | (1.9M) | 154K | 2.0M | 1.8M | 2.1M | |
Operating Income | (21.6M) | (35.5M) | (19.4M) | (13.9M) | (12.5M) | (13.2M) | |
Ebit | (6.1M) | (24.3M) | (15.0M) | (13.9M) | (12.5M) | (13.1M) | |
Research Development | 8.0M | 3.9M | 1.5M | 1.4M | 1.2M | 1.2M | |
Ebitda | (5.4M) | (23.3M) | (13.6M) | (13.6M) | (12.2M) | (12.8M) | |
Cost Of Revenue | 5.2M | 8.7M | 9.8M | 3.3M | 3.8M | 3.1M | |
Income Before Tax | (6.2M) | (16.1M) | (15.6M) | (13.2M) | (11.8M) | (12.4M) | |
Net Income | (6.0M) | (16.1M) | (15.6M) | (14.0M) | (16.1M) | (16.9M) | |
Tax Provision | 10K | 2K | (124K) | 14K | 12.6K | 13.2K | |
Net Interest Income | (47K) | (789K) | 289K | 704K | 809.6K | 850.1K | |
Minority Interest | 827K | 1.5M | 236K | 89K | 80.1K | 76.1K |
Arcadia Biosciences Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (9.8M) | (2.4M) | 1.1M | 444K | 399.6K | 419.6K | |
Change In Cash | 7.6M | 12.6M | (8.0M) | (14.1M) | (12.7M) | (12.1M) | |
Free Cash Flow | (32.6M) | (26.9M) | (14.0M) | (15.3M) | (13.8M) | (14.5M) | |
Depreciation | 662K | 1.0M | 479K | 984K | 1.1M | 1.2M | |
Other Non Cash Items | (15.3M) | 492K | (1M) | 499K | 449.1K | 471.6K | |
Capital Expenditures | 2.3M | 1.0M | 72K | 5K | 5.8K | 5.5K | |
Net Income | (6.0M) | (16.1M) | (15.6M) | (14.0M) | (16.1M) | (16.9M) | |
End Period Cash Flow | 16.0M | 28.7M | 20.6M | 6.5M | 7.5M | 13.9M | |
Investments | 20.1M | 16.6M | 1.4M | (4.1M) | (4.7M) | (4.5M) | |
Change To Netincome | (7.7M) | 10.8M | (14.9M) | (9.3M) | (8.3M) | (7.9M) |
Arcadia Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcadia Biosciences's current stock value. Our valuation model uses many indicators to compare Arcadia Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcadia Biosciences competition to find correlations between indicators driving Arcadia Biosciences's intrinsic value. More Info.Arcadia Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Arcadia Biosciences' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arcadia Biosciences' earnings, one of the primary drivers of an investment's value.Arcadia Biosciences Systematic Risk
Arcadia Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arcadia Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Arcadia Biosciences correlated with the market. If Beta is less than 0 Arcadia Biosciences generally moves in the opposite direction as compared to the market. If Arcadia Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arcadia Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arcadia Biosciences is generally in the same direction as the market. If Beta > 1 Arcadia Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Arcadia Biosciences Thematic Clasifications
Arcadia Biosciences is part of several thematic ideas from Natural Foods to Agriculture. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Arcadia Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcadia Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arcadia Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Arcadia Biosciences March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arcadia Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arcadia Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arcadia Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Arcadia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcadia Biosciences's daily price indicators and compare them against related drivers.
Information Ratio | (0.20) | |||
Maximum Drawdown | 26.92 | |||
Value At Risk | (6.87) | |||
Potential Upside | 4.49 |
Complementary Tools for Arcadia Stock analysis
When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |